Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination (Q36445546)

14 August 2017

1 reference

title

Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination (English)

1 reference

14 August 2017

1 reference

1 reference

Gentao Liu

1

1 reference

PubMed ID

16608423

14 August 2017

Keith L Black

series ordinal

2

1 reference

PubMed ID

16608423

14 August 2017

John S Yu

series ordinal

3

1 reference

14 August 2017

1 April 2006

1 reference

Expert Review of Vaccines

14 August 2017

1 reference

14 August 2017

5

1 reference

14 August 2017

2

1 reference

14 August 2017

233-247

1 reference

Brain-tumour drug resistance: the bare essentials

14 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

A role for intracellular immunization in chemosensitization of tumor cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Human tumor antigens for cancer vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Regulation of tyrosinase-related protein-2 (TYRP2) in human melanocytes: relationship to growth and morphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

The neu oncogene encodes an epidermal growth factor receptor-related protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Expression of multidrug resistance protein gene in patients with glioma after chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

EphA2 as a glioma-associated antigen: a novel target for glioma vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Apoptosis pathways in neuroblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Overexpression of bax in human glioma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells: role of c-jun in drug resistance and cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

p27 modulates cell cycle progression and chemosensitivity in human malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Universal tumor antigens as targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Quantitatively determined survivin expression levels are of prognostic value in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Cancer vaccines and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

AIM-2: a novel tumor antigen is expressed and presented by human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Dendritic cell immunotherapy: mapping the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Immunotherapy of malignant brain tumors in children and adults: from theoretical principles to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: A toxicity study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Thymic CD8+ T Cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Synergy between tumor immunotherapy and antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Expression of the Gene for Multidrug-Resistance–Associated Protein and Outcome in Patients with Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Expression of tyrosinase, TRP-1 and TRP-2 in ultraviolet-irradiated human melanomas and melanocytes: TRP-2 protects melanoma cells from ultraviolet B induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

Immunotherapy and chemotherapy--a practical partnership

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.233

21 January 2018

Identifiers

DOI

10.1586/14760584.5.2.233

1 reference

14 August 2017

1 reference

PubMed ID

16608423